CGEN

Compugen Ltd

Add to Watchlist

Advanced Chart

1.440

-0.04(-2.703%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.490

Open

1.480

VWAP

1.48

Vol

185.63K

Mkt Cap

128.94M

Low

1.440

Amount

274.46K

EV/EBITDA(TTM)

Total Shares

89.53M

25.19M

EV/OCF(TTM)

P/S(TTM)

4.71

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

4.43M

+201.29%

4.10M

-76.06%

3.95M

-41.03%

Estimates Revision

The market is revising Upward the revenue expectations for Compugen Ltd. (CGEN) for FY2025, with the revenue forecasts being adjusted by 49.37% over the past three months. During the same period, the stock price has changed by -5.26%.

Revenue Estimates for FY2025

Revise Upward

+49.37%

In Past 3 Month

Stock Price

Go Down

-5.26%

In Past 3 Month

3 Analyst Rating

386.11% Upside

Wall Street analysts forecast CGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGEN is 7.00 USD with a low forecast of 4.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

386.11% Upside

Current: 1.440

Low

4.00

Averages

7.00

High

10.00

386.11% Upside

Current: 1.440

Low

4.00

Averages

7.00

High

10.00

The End

See All Ratings

No Data

Valuation Metrics

The current forward P/E ratio for Compugen Ltd (CGEN.O) is -4.74, compared to its 5-year average forward P/E of -30.29. For a more detailed relative valuation and DCF analysis to assess Compugen Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-30.29

Current PE

-4.74

Overvalued PE

16.31

Undervalued PE

-76.89

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.87

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

5.69

Undervalued EV/EBITDA

-11.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

37.23

Current PS

11.31

Overvalued PS

159.36

Undervalued PS

-84.90